Cyamemazine
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Overview
Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class which was introduced by Theraplix in France in 1972 and later in Portugal as well.[1][2][3][4] It is used for the treatment of schizophrenia and, especially, for psychosis-associated anxiety, due to its unique anxiolytic efficacy.[5][6]
Cyamemazine differs from other phenothiazine neuroleptics in that aside from the usual profile of dopamine, α1-adrenergic, H1, and mACh receptor antagonism,[7] it additionally produces potent blockade of several serotonin receptors, including 5-HT2A, 5-HT2C, and 5-HT7.[7][8][9][10] These actions have been implicated in cyamemazine’s anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A),[7][8] and despite being classified as a typical, it actually behaves like an atypical antipsychotic.[11]
References
References
- ↑ Index nominum, international drug … – Google Books.
- ↑ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. p. 534. ISBN 0-412-46630-9.
- ↑ Pharmaceutical manufacturing … – Google Books.
- ↑ Bret P, Bret MC, Queuille E (April 2009). “[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals]”. L’Encéphale (in French). 35 (2): 129–38. doi:10.1016/j.encep.2008.03.007. PMID 19393381.
- ↑ “Stahl’s Essential Psychopharmacology – Cambridge University Press”.
- ↑ Bourin M, Nic Dhonnchadha BA, Claude Colombel M, Dib M, Hascoët M (September 2001). “Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice”. Behavioural Brain Research. 124 (1): 87–95. doi:10.1016/S0166-4328(01)00238-8. PMID 11423169.
- ↑ 7.0 7.1 7.2 Hameg A, Bayle F, Nuss P, Dupuis P, Garay RP, Dib M (February 2003). “Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes”. Biochemical Pharmacology. 65 (3): 435–40. doi:10.1016/S0006-2952(02)01515-0. PMID 12527336.
- ↑ 8.0 8.1 Alvarez-Guerra M, d’Alché-Birée F, Wolf WA, Vargas F, Dib M, Garay RP (January 2000). “5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity”. Psychopharmacology. 147 (4): 412–7. doi:10.1007/s002130050010. PMID 10672635.
- ↑ Alvarez-Guerra M, Hameg A, Bayle F, Dib M, Garay RP (November 2002). “5-HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle”. European Journal of Pharmacology. 454 (2–3): 235–9. doi:10.1016/S0014-2999(02)02489-5. PMID 12421652.
- ↑ Benyamina A, Arbus C, Nuss P, Garay RP, Neliat G, Hameg A (January 2008). “Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes”. European Journal of Pharmacology. 578 (2–3): 142–7. doi:10.1016/j.ejphar.2007.09.025. PMID 17936750.
- ↑ Peinado J, Hameg A, Garay RP, Bayle F, Nuss P, Dib M (February 2003). “Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine”. Naunyn-Schmiedeberg’s Archives of Pharmacology. 367 (2): 134–9. doi:10.1007/s00210-002-0665-4. PMID 12595954.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH